Protagonist Therapeutics Inc (NASDAQ:PTGX) major shareholder X L.P. Canaan sold 77,591 shares of the business’s stock in a transaction on Monday, May 14th. The shares were sold at an average price of $6.37, for a total value of $494,254.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

X L.P. Canaan also recently made the following trade(s):

  • On Wednesday, May 16th, X L.P. Canaan sold 164,747 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $6.42, for a total value of $1,057,675.74.
  • On Thursday, March 22nd, X L.P. Canaan sold 39,518 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $20.61, for a total value of $814,465.98.
  • On Monday, March 19th, X L.P. Canaan sold 20,365 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $20.55, for a total value of $418,500.75.
  • On Tuesday, March 13th, X L.P. Canaan sold 1,204 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $20.84, for a total value of $25,091.36.
  • On Thursday, March 15th, X L.P. Canaan sold 13,155 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $20.66, for a total value of $271,782.30.

Shares of Protagonist Therapeutics opened at $5.99 on Friday, according to MarketBeat. Protagonist Therapeutics Inc has a 1-year low of $6.34 and a 1-year high of $6.50.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Wednesday, May 9th. The company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.07). The business had revenue of $10.78 million during the quarter, compared to the consensus estimate of $10.70 million. equities research analysts predict that Protagonist Therapeutics Inc will post -0.98 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Farallon Capital Management LLC increased its holdings in Protagonist Therapeutics by 12.6% during the 1st quarter. Farallon Capital Management LLC now owns 1,013,500 shares of the company’s stock worth $8,706,000 after purchasing an additional 113,500 shares during the period. BlackRock Inc. increased its holdings in shares of Protagonist Therapeutics by 39.0% in the 1st quarter. BlackRock Inc. now owns 687,160 shares of the company’s stock valued at $5,904,000 after acquiring an additional 192,632 shares during the last quarter. First Manhattan Co. increased its holdings in shares of Protagonist Therapeutics by 2,408.2% in the 4th quarter. First Manhattan Co. now owns 416,364 shares of the company’s stock valued at $8,660,000 after acquiring an additional 399,764 shares during the last quarter. BVF Inc. IL increased its holdings in shares of Protagonist Therapeutics by 37.9% in the 1st quarter. BVF Inc. IL now owns 405,600 shares of the company’s stock valued at $3,484,000 after acquiring an additional 111,483 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Protagonist Therapeutics by 66.4% in the 1st quarter. Millennium Management LLC now owns 320,739 shares of the company’s stock valued at $2,755,000 after acquiring an additional 128,009 shares during the last quarter. Institutional investors own 56.00% of the company’s stock.

Several equities research analysts have weighed in on the company. Zacks Investment Research downgraded Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 11th. BMO Capital Markets restated an “outperform” rating and set a $13.00 price target (down previously from $42.00) on shares of Protagonist Therapeutics in a report on Monday, March 26th. They noted that the move was a valuation call. Stifel Nicolaus downgraded Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, March 26th. Finally, BidaskClub downgraded Protagonist Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, March 23rd. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $26.75.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Insider Buying and Selling by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.